I am thrilled to share this viewpoint essay about my first year as a #cancerresearch PI. Our lab just turned one & this was the perfect opportunity to reminisce on the journey thus far. It has only begun, excited for it all. Grateful to @NatureCancer for inviting me to share this

Beyond grateful to share that my main PhD thesis project, Targeting PIKfyve-driven lipid metabolism in pancreatic cancer (@LyssiotisLab @ArulChinnaiyan), has just been published in @Nature! @UMRogelCancer @UMICHpancreas @UMichMedSchool @UMichPath @UMichResearch @UMichCMB

Termination of the integrated stress response | Science

New story from the O’Donnell Lab on how an acidified TME remodels the immune compartment in LUSC. Congrats to the entire team! 🤩

We are happy to announce that the first paper from the Najafov Lab has been published in @Nature! In this study, we identified SIGLEC12 as a mediator of plasma membrane rupture (PMR) for necroptotic cell death using a genome-wide CRISPR-based systematic approach. @UTSWMedCenter

🗨️ Just published in @NatureBiotech: Our CellWhisperer AI enables chat-based analysis of single-cell sequencing data. You can talk to your cells & figure out the biology without writing any computer code. Paper link and annotated walkthrough in the thread below (1/11)

Wonderful summary resource from @CancerResearch @ay_zhou et al: The global landscape of cancer cell therapies, clinical trial trends and emerging directions https://t.co/v5YDLlBDbB @NatRevDrugDisc

CSIR -IGIB welcomed the Parliamentary Standing Committee on Science and Technology, Environment, Forest and Climate Change today. Members of Parliament interacted with the students and scientists at length. @PMOIndia @DrJitendraSingh @PrinSciAdvOff @BKalitaAssam @krsureshreddy

Two new Nature papers show that inhibiting FSP1 is sufficient to restrict tumor growth in vivo, a major step forward for ferroptosis-targeted cancer therapy. Huge congrats to all authors! https://t.co/ezDfPzSqvK https://t.co/uaYWXKoi87 #Ferroptosis #FSP1 #CancerResearch

Where do cancers start? In the liver, not all cells are the same. The liver is divided into 3 “zones,” and each specializes in different metabolic tasks. We show in @Science that where a mutation occurs in a liver lobule can determine a cell’s fate. https://t.co/3YTc77gZcd (1/9)

Excited to share our paper on a dramatic case of cancer lineage plasticity: melanoma to rhabdomyosarcoma transformation during ICB. Always fun working w/ Ryan Sullivan, David Liu, Keith Flaherty, Peter Sorger, among others. @MGHCancerCenter @broadinstitute

The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early https://t.co/dC9vo81f7e

Secretome translation shaped by lysosomes and lunapark-marked ER junctions https://t.co/BVWbFONE0T

Too many men die of prostate cancer. We miss you John. We discovered a new way of attacking androgen receptor driven prostate cancers that will lead to new therapeutics. This was a wonderful collaboration with @li_haolong and Felix Feng (rest in peace). https://t.co/24bBKLdWus

Excited to share our new work demonstrating that RAS-ON inhibitors have activity in NRAS mutant melanoma preclinical models and in melanoma patients! @MoffittNews @MelanomaReAlli @CureMelanoma

Phagocytosis: a process that shapes immune responses to engulfed meals

This is what the last five years have been about! Incredibly proud to share our new paper in Nature Genetics: “Transcription Factor Switching Drives Subtype Specific Pancreatic Cancer.” Thank you @JCarrollLab @PancreaticCanUK @CRUK_CI https://t.co/tu5do3uRE7

Excited to see my PhD work out! Here, we find an unexpected epigenetic mechanism that regulates oncogene amplification to promote tyrosine kinase inhibitor resistance in lung adenocarcinoma. Tweetorial below! ⬇️ https://t.co/2AL1TMZiG0

.@NatureGenet paper by @BizarMd @columbiacancer Cellular states associated with metastatic organotropism & survival in patients with #PancreaticCancer “pre-existing cellular states within primary tumors appear to guide organ-specific metastatic relapse” https://t.co/omZzPO6P78

Congratulations to my PhD student Tim Arnoldus @NKI_nl @oncodeinstitute on publishing his discovery today in Nature Genetics! 🎉 Taking a computational approach, Tim found a synthetic lethal target that may impact future treatment of half of all cancers👏 https://t.co/cQdeYQinsX

New causal genetic evidence shows it's likely that statins (HMGCR), PCSK9 inhibitors, ezetimibe (NPC1L1), and other cholesterol lowering drugs not only reduce heart disease risk, but also prevent dementia!